Kari T Kivistö, Mikko Niemi, Elke Schaeffeler, Kaisu Pitkälä, Reijo Tilvis, Martin F Fromm, Matthias Schwab, Florian Lang, Michel Eichelbaum, Timo Strandberg
{"title":"CYP3A5基因型与老年高血压患者的诊断相关:来自DEBATE研究的数据","authors":"Kari T Kivistö, Mikko Niemi, Elke Schaeffeler, Kaisu Pitkälä, Reijo Tilvis, Martin F Fromm, Matthias Schwab, Florian Lang, Michel Eichelbaum, Timo Strandberg","doi":"10.2165/00129785-200505030-00005","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension.</p><p><strong>Method: </strong>We studied 373 elderly (age > or =75 years) Finnish (Caucasian) patients from the ongoing DEBATE (Drugs and Evidence Based Medicine in the Elderly) trial. The patients were classified into those with a history of hypertension (n = 229) and those without a history of hypertension (n = 144) on the basis of a detailed questionnaire on each patient's medical history and an interview. The patients were genotyped for the CYP3A5 6986A/G single nucleotide polymorphism (SNP) [CYP3A5*1/*3 alleles].</p><p><strong>Results: </strong>The proportion of individuals with the CYP3A5*1/*3 genotype, i.e. CYP3A5 expressors, was significantly higher among patients with a diagnosis of hypertension than among patients without (18.3% vs 9.0%, p = 0.016). The corresponding odds ratio was 2.26 (95% CI 1.17, 4.38). The allele and genotype frequencies for the two control SNPs, ABCB1 (MDR1) 3435C/T and SLCO1B1 521T/C, did not differ between the two groups.</p><p><strong>Conclusion: </strong>This work lends support to the theory that the polymorphic CYP3A5 enzyme may be involved in regulation of blood pressure. The possible role of CYP3A5 as a genetic contributor to hypertension susceptibility warrants further study.</p>","PeriodicalId":72171,"journal":{"name":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00129785-200505030-00005","citationCount":"43","resultStr":"{\"title\":\"CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.\",\"authors\":\"Kari T Kivistö, Mikko Niemi, Elke Schaeffeler, Kaisu Pitkälä, Reijo Tilvis, Martin F Fromm, Matthias Schwab, Florian Lang, Michel Eichelbaum, Timo Strandberg\",\"doi\":\"10.2165/00129785-200505030-00005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension.</p><p><strong>Method: </strong>We studied 373 elderly (age > or =75 years) Finnish (Caucasian) patients from the ongoing DEBATE (Drugs and Evidence Based Medicine in the Elderly) trial. The patients were classified into those with a history of hypertension (n = 229) and those without a history of hypertension (n = 144) on the basis of a detailed questionnaire on each patient's medical history and an interview. The patients were genotyped for the CYP3A5 6986A/G single nucleotide polymorphism (SNP) [CYP3A5*1/*3 alleles].</p><p><strong>Results: </strong>The proportion of individuals with the CYP3A5*1/*3 genotype, i.e. CYP3A5 expressors, was significantly higher among patients with a diagnosis of hypertension than among patients without (18.3% vs 9.0%, p = 0.016). The corresponding odds ratio was 2.26 (95% CI 1.17, 4.38). The allele and genotype frequencies for the two control SNPs, ABCB1 (MDR1) 3435C/T and SLCO1B1 521T/C, did not differ between the two groups.</p><p><strong>Conclusion: </strong>This work lends support to the theory that the polymorphic CYP3A5 enzyme may be involved in regulation of blood pressure. The possible role of CYP3A5 as a genetic contributor to hypertension susceptibility warrants further study.</p>\",\"PeriodicalId\":72171,\"journal\":{\"name\":\"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2165/00129785-200505030-00005\",\"citationCount\":\"43\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2165/00129785-200505030-00005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00129785-200505030-00005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 43
摘要
目的:本研究的目的是解决目前有争议的问题,即细胞色素P450 (CYP) 3A5多态性是否与高血压有关。方法:我们研究了373名老年(年龄>或=75岁)芬兰(高加索)患者,他们来自正在进行的DEBATE(老年药物和循证医学)试验。通过对患者进行详细的病史问卷调查和访谈,将患者分为有高血压史(229例)和无高血压史(144例)。对患者进行CYP3A5 6986A/G单核苷酸多态性(SNP) [CYP3A5*1/*3等位基因]基因分型。结果:诊断为高血压的患者中CYP3A5*1/*3基因型(即CYP3A5表达物)个体比例显著高于未诊断为高血压的患者(18.3% vs 9.0%, p = 0.016)。相应的优势比为2.26 (95% CI 1.17, 4.38)。ABCB1 (MDR1) 3435C/T和SLCO1B1 521T/C两个对照snp的等位基因频率和基因型频率在两组间无差异。结论:本研究支持CYP3A5酶多态性可能参与血压调节的理论。CYP3A5作为高血压易感性遗传因素的可能作用值得进一步研究。
CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
Objective: The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension.
Method: We studied 373 elderly (age > or =75 years) Finnish (Caucasian) patients from the ongoing DEBATE (Drugs and Evidence Based Medicine in the Elderly) trial. The patients were classified into those with a history of hypertension (n = 229) and those without a history of hypertension (n = 144) on the basis of a detailed questionnaire on each patient's medical history and an interview. The patients were genotyped for the CYP3A5 6986A/G single nucleotide polymorphism (SNP) [CYP3A5*1/*3 alleles].
Results: The proportion of individuals with the CYP3A5*1/*3 genotype, i.e. CYP3A5 expressors, was significantly higher among patients with a diagnosis of hypertension than among patients without (18.3% vs 9.0%, p = 0.016). The corresponding odds ratio was 2.26 (95% CI 1.17, 4.38). The allele and genotype frequencies for the two control SNPs, ABCB1 (MDR1) 3435C/T and SLCO1B1 521T/C, did not differ between the two groups.
Conclusion: This work lends support to the theory that the polymorphic CYP3A5 enzyme may be involved in regulation of blood pressure. The possible role of CYP3A5 as a genetic contributor to hypertension susceptibility warrants further study.